|
KMID : 1148920180520040266
|
|
Nuclear Medicine and Molecular Imaging
2018 Volume.52 No. 4 p.266 ~ p.278
|
|
|
Emerging Tracers for Nuclear Cardiac PET Imaging
|
|
Kim Dong-Yeon
Cho Sang-Geon
Bom Hee-Seung
|
|
|
Abstract
|
|
|
|
Myocardial perfusion imaging using positron emission tomography (PET) has several advantages over single photon emission computed tomography (SPECT). The recent advances in SPECT technology have shown promise, but there is still a large need for PET in the clinical management of coronary artery disease (CAD). Especially, absolute quantification of myocardial blood flow (MBF) using PET is extremely important. In spite of considerable advances in the diagnosis of CAD, novel PET radiopharmaceuticals remain necessary for the diagnosis of CAD because clinical use of current cardiac radiotracers is limited by their physical characteristics, such as decay mode, emission energy, and half-life. Thus, the use of a radioisotope that has proper characteristics and a proper half-life to develop myocardial perfusion agents could overcome these limitations. In this review, the current state of cardiac PET and a general overview of novel 18F or 68Ga-labeled radiotracers, including their radiosynthesis, in vivo characterization, and evaluation, are provided. The future perspectives are discussed in terms of their potential usefulness based on new image analysis methods and hybrid imaging.
|
|
|
KEYWORD
|
|
|
Coronary artery disease (CAD), Myocardial imaging agents, 18F-labeled mitochondrial voltage sensors, 68Ga-labeled cardiac imaging agents, Positron emission tomography
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|